Sign in

You're signed outSign in or to get full access.

RK

Managing Director and Senior Healthcare Analyst at HC Wainright

Raghuram Selvaraju, Ph.D., is a Managing Director and Senior Healthcare Analyst at H.C. Wainwright, focusing on healthcare sector research, particularly in biotechnology, pharma, and related industries. He has covered and published on a broad range of companies across drug development, with demonstrated success including rankings by StarMine for earnings accuracy and recognition in The Wall Street Journal’s Best on the Street Analyst awards for stock-picking performance. With more than a decade of experience, Dr. Selvaraju previously held senior research roles at MLV & Co., Aegis Capital, Hapoalim Securities USA, and Rodman & Renshaw before joining H.C. Wainwright. He holds a Ph.D. in molecular neuroscience and cellular immunology, an M.S. in molecular biology from the University of Geneva, and an MBA from Cornell University.

RK's questions to MediWound (MDWD) leadership

Question · Q3 2025

RK asked for a breakdown of the $830 million EscharEx peak sales projection between DFU and VLU opportunities. He also inquired about the status and timing of the BARDA RFP, and the impact of not having a permanent CPT code for NexoBrid on adoption, as well as the benefits a permanent code would bring.

Answer

Barry Wolfenson, EVP of Strategy and Corporate Development, explained that the DFU and VLU opportunities for EscharEx are roughly even, with a slight weighting towards VLU due to the pain associated with venous leg ulcers. Ofer Gonen, CEO, confirmed that the BARDA RFP for a 10-year contract (stockpiling, room-temp stable formulation, trauma/blast injury) is awaiting contract signing, with activities paused due to the government shutdown but expected to resume soon. Barry Wolfenson added that while NexoBrid has a temporary CPT code, a permanent one would enhance national and institutional legitimacy, standardize language, and ease approval pathways, thereby boosting physician and burn center adoption.

Ask follow-up questions

Fintool

Fintool can predict MediWound logo MDWD's earnings beat/miss a week before the call

RK's questions to CollPlant Biotechnologies (CLGN) leadership

Question · Q4 2024

The analyst inquired about the timeline for updates and potential milestone payments from the AbbVie collaboration, as well as the market potential and expected revenue flow from the expanded distribution of the Vergenix product.

Answer

The company stated that the timeline for the AbbVie program is determined by AbbVie, and they cannot estimate future milestone payments. Regarding Vergenix, the product targets the tendinopathy market, and the company is establishing distribution networks in Europe and Asia, hoping to see sales in the next year after securing regulatory approvals.

Ask follow-up questions

Fintool

Fintool can predict CollPlant Biotechnologies logo CLGN's earnings beat/miss a week before the call

RK's questions to HOOKIPA Pharma (HOOK) leadership

Question · Q4 2021

RK from H.C. Wainwright inquired about the expected content of the four upcoming presentations at the AACR conference. He also asked about the development plan and timeline for the HB-700 KRAS program and whether its progress is contingent on milestones from the HB-200 or HB-300 programs.

Answer

Igor Matushansky, CMO & Global Head of R&D, stated the AACR presentations will cover preclinical, translational, and biomarker data, including updates on the prostate cancer (HB-300) and HB-200 programs. He confirmed the HB-700 program is not dependent on further clinical data from other assets and will proceed once manufacturing is ready. CEO Joern Aldag clarified the IND filing for HB-700 is anticipated in 2023 or beyond.

Ask follow-up questions

Fintool

Fintool can predict HOOKIPA Pharma logo HOOK's earnings beat/miss a week before the call